Yescarta Archives -

Market Access/ News/ News/ News/ Oncology

Kymriah is first CAR-T cleared for follicular lymphoma in EU

Phil Taylor CAR-T therapies, cell therapy, Gilead Sciences, immuno-oncology, Kymriah, Novartis, Oncology, regulatory approval, Yescarta 0 Comment

Novartis’ CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of

Kymriah is first CAR-T cleared for follicular lymphoma in EU

https://pharmaphorum.com/news/kymriah-is-first-car-t-cleared-for-follicular-lymphoma-in-eu/

News/ News/ Oncology

Gilead beats BMS to FDA okay for early lymphoma CAR-T therapy

Phil Taylor Breyanzi, Bristol-Myers Squibb, CAR-T therapies, Gilead Sciences, lymphoma, Oncology, regulatory approval, Yescarta 0 Comment

Gilead Sciences’ Kite Pharma has become the first drugmaker to get FDA approval to use a CAR-T therapy

Gilead beats BMS to FDA okay for early lymphoma CAR-T therapy

https://pharmaphorum.com/news/gilead-beats-bms-to-fda-okay-for-early-lymphoma-car-t-therapy/

News/ News/ Oncology

ASH: Trial backs Gilead’s Yescarta CAR-T in first-line lymphoma

Phil Taylor CAR-T therapies, Gilead Sciences, immuno-oncology, non-Hodgkin lymphoma, Oncology, Yescarta 0 Comment

Gilead Sciences has taken a big step towards positioning its CAR-T therapy Yescarta as an option for previously-untreated

ASH: Trial backs Gilead’s Yescarta CAR-T in first-line lymphoma

https://pharmaphorum.com/news/ash-trial-backs-gileads-yescarta-car-t-in-first-line-lymphoma/

News/ News/ Oncology

ASH: Gilead, BMS CAR-Ts square off in relapsed lymphoma

Phil Taylor Breyanzi, Bristol-Myers Squibb, Gilead Sciences, immuno-oncology, non-Hodgkin lymphoma, Oncology, Yescarta 0 Comment

A pair of trials have suggested that CAR-T therapies could offer an improved option for patients with large

ASH: Gilead, BMS CAR-Ts square off in relapsed lymphoma

https://pharmaphorum.com/news/ash-gilead-bms-car-ts-square-off-in-relapsed-lymphoma/

News/ News/ Oncology

AZ, HutchMed’s savolitinib gets 1st approval in China for NSCLC

Phil Taylor AstraZeneca, CAR-T therapies, China, Gilead Sciences, HutchMed, immuno-oncology, lung cancer, Non-small cell lung cancer, Oncology, Orpathys, savolitinib, Yescarta 0 Comment

AstraZeneca and HutchMed have claimed their first approval – in China – for cMET inhibitor savolitinib as a

AZ, HutchMed’s savolitinib gets 1st approval in China for NSCLC

https://pharmaphorum.com/news/az-hutchmeds-savolitinib-gets-1st-approval-in-china-for-nsclc/

R&D/ Views & Analysis/ Views and analysis

Casting aside CRISPR scissors and making a point with base editors

mike.hammerton@pharmaphorum.com CRISPR, gene editing, immune cell therapy, Kymriah, Perkin Elmer, Yescarta 0 Comment

Dr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at

Casting aside CRISPR scissors and making a point with base editors

https://pharmaphorum.com/r-d/views-analysis-r-d/immune-cell-therapies-crispr-cas9-gene-editing/

Market Access/ News/ News/ News/ News/ Oncology/ Patients

Scotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphoma

Phil Taylor CAR T, Gilead Sciences, NHS, non-Hodgkin lymphoma, Oncology, Scotland, Yescarta 0 Comment

The Scottish Medicines Consortium has backed NHS funding for Gilead’s CAR-T therapy Yescarta for B-cell lymphomas, a few

Scotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphoma

https://pharmaphorum.com/news/scotland-says-yes-to-gileads-car-t-yescarta-for-lymphoma/

R&D/ Views & Analysis/ Views and analysis

Will cell and gene therapies disrupt reimbursement?

Dominic Tyer cell and gene therapy, cell therapy, Deep Dive: Disruptive Technologies, gene therapy, Kymriah, Luxturna, PhRMA, Yescarta 0 Comment

Cell and gene therapies could prove disruptive in terms of the life-changing benefits they could bring to people

Will cell and gene therapies disrupt reimbursement?

https://pharmaphorum.com/r-d/cell-gene-therapy-reimbursement/

News/ News/ R&D

Scotland says no to Yescarta, but backs Kymriah

Phil Taylor Kymriah, leukaemia, SMC, Yescarta 0 Comment

Scotland’s cost-effectiveness watchdog has decided against making Gilead’s CAR-T therapy Yescarta routinely available to patients with two types

Scotland says no to Yescarta, but backs Kymriah

https://pharmaphorum.com/news/scotland-says-no-to-yescarta-but-backs-kymriah/

Trending

Yescarta

Login